Total Payments
$116,660
2024 Payments
$118.59
Companies
5
Transactions
131
Medicare Patients
2,871
Medicare Billing
$227,113
Payment Breakdown by Category
Other$83,232 (71.3%)
Consulting$17,220 (14.8%)
Travel$13,532 (11.6%)
Food & Beverage$2,664 (2.3%)
Education$12.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $83,232 | 29 | 71.3% |
| Consulting Fee | $17,220 | 6 | 14.8% |
| Travel and Lodging | $13,532 | 42 | 11.6% |
| Food and Beverage | $2,664 | 53 | 2.3% |
| Education | $12.59 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $113,396 | 125 | $0 (2024) |
| Nabriva Therapeutics, plc | $1,788 | 2 | $0 (2022) |
| United Therapeutics Corporation | $1,348 | 1 | $0 (2021) |
| Genentech USA, Inc. | $97.35 | 1 | $0 (2017) |
| Merck Sharp & Dohme LLC | $30.90 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $118.59 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($118.59) |
| 2023 | $9,585 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,567) |
| 2022 | $1,848 | 3 | Nabriva Therapeutics, plc ($1,788) |
| 2021 | $3,688 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($2,340) |
| 2020 | $12.59 | 1 | Merck Sharp & Dohme Corporation ($12.59) |
| 2018 | $47,707 | 59 | Boehringer Ingelheim Pharmaceuticals, Inc. ($47,707) |
| 2017 | $53,701 | 61 | Boehringer Ingelheim Pharmaceuticals, Inc. ($53,603) |
All Payment Transactions
131 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $118.59 | General |
| 10/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $81.20 | General |
| 10/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $33.61 | General |
| 02/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $9,452.25 | General |
| Category: RESPIRATORY | ||||||
| 01/05/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/16/2022 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV | Food and Beverage | In-kind items and services | $59.91 | General |
| 04/26/2022 | Nabriva Therapeutics, plc | Xenleta (Drug) | Consulting Fee | Cash or cash equivalent | $1,750.00 | General |
| Category: Antibiotic | ||||||
| 04/26/2022 | Nabriva Therapeutics, plc | Xenleta (Drug) | Food and Beverage | In-kind items and services | $38.27 | General |
| Category: Antibiotic | ||||||
| 10/22/2021 | United Therapeutics Corporation | — | Consulting Fee | Cash or cash equivalent | $1,347.50 | General |
| 05/25/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: RESPIRATORY | ||||||
| 02/04/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/07/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,040.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $145.14 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $24.00 | General |
| Category: ONCOLOGY | ||||||
| 07/06/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ONCOLOGY | ||||||
| 07/05/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $681.00 | General |
| Category: ONCOLOGY | ||||||
| 06/22/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,850.00 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $904.42 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $107.11 | General |
| 06/06/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $45.51 | General |
| Category: ONCOLOGY | ||||||
| 05/21/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,230.00 | General |
| 05/10/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,230.00 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $116.63 | General |
| Category: ONCOLOGY | ||||||
| 05/10/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $113.44 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 699 | 821 | $197,179 | $43,372 |
| 2022 | 12 | 733 | 982 | $265,051 | $59,388 |
| 2021 | 13 | 903 | 1,133 | $315,462 | $73,008 |
| 2020 | 14 | 536 | 712 | $231,034 | $51,345 |
Total Patients
2,871
Total Services
3,648
Medicare Billing
$227,113
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 50 | 78 | $72,774 | $12,640 | 17.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 113 | $37,968 | $10,152 | 26.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 28 | 31 | $14,384 | $4,183 | 29.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $12,616 | $3,231 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 31 | $10,664 | $2,893 | 27.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 20 | $13,080 | $2,764 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 33 | 37 | $8,584 | $2,454 | 28.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 31 | $7,254 | $1,819 | 25.1% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2023 | 174 | 179 | $5,728 | $1,166 | 20.4% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2023 | 95 | 97 | $4,656 | $861.98 | 18.5% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2023 | 116 | 118 | $3,776 | $691.98 | 18.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2023 | 66 | 67 | $5,695 | $517.10 | 9.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 54 | 113 | $105,429 | $20,876 | 19.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 80 | 239 | $80,304 | $19,790 | 24.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 26 | $12,064 | $3,736 | 31.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 24 | 24 | $15,696 | $3,571 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 26 | $8,944 | $2,516 | 28.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 37 | $8,658 | $2,063 | 23.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 11 | 11 | $7,304 | $1,669 | 22.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 24 | $5,568 | $1,623 | 29.1% |
| 94729 | Test to examine how well the lungs exchange gases | Facility | 2022 | 175 | 178 | $4,806 | $1,200 | 25.0% |
| 94726 | Test to determine lung volumes using sensors | Facility | 2022 | 105 | 105 | $4,515 | $948.98 | 21.0% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Facility | 2022 | 105 | 107 | $9,095 | $828.04 | 9.1% |
| 94010 | Test to measure expiratory airflow and volume | Facility | 2022 | 91 | 92 | $2,668 | $566.65 | 21.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 72 | 155 | $144,615 | $30,372 | 21.0% |
About Dr. Corey Kershaw, MD
Dr. Corey Kershaw, MD is a Critical Care Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811939325.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Corey Kershaw, MD has received a total of $116,660 in payments from pharmaceutical and medical device companies, with $118.59 received in 2024. These payments were reported across 131 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($83,232).
As a Medicare-enrolled provider, Kershaw has provided services to 2,871 Medicare beneficiaries, totaling 3,648 services with total Medicare billing of $227,113. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease, Pulmonary Disease
- Location Dallas, TX
- Active Since 06/11/2006
- Last Updated 04/15/2010
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1811939325
Products in Payments
- OFEV (Drug) $91,725
- Xenleta (Drug) $1,788
- Esbriet (Biological) $97.35
- DIFICID (Drug) $18.31
- ZERBAXA (Drug) $12.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Dallas
Dr. Yolanda Mageto, Md, MD
Critical Care Medicine — Payments: $248,495
Critical Care Medicine $248,495
Sonja Bartolome, M.d, M.D
Critical Care Medicine — Payments: $194,111
Critical Care Medicine $194,111
Dr. Jagadeshwar Reddy, M.d, M.D
Critical Care Medicine — Payments: $10,977
Critical Care Medicine $10,977
Mr. Humayun Anjum, M.d, M.D
Critical Care Medicine — Payments: $10,184
Critical Care Medicine $10,184
Todd Grazia, Md, MD
Critical Care Medicine — Payments: $8,074
Critical Care Medicine $8,074
Joseph Crossno, Md, MD
Critical Care Medicine — Payments: $7,530
Critical Care Medicine $7,530